Kornimate/medical-research-clean huggingface dataset:
powered assist hip exoskeleton to improve ambulation in severe lung disease

Conditions: Lung Disease Chronic

Summary: chronic respiratory disease (crd) is among the most prevalent and growing diseases worldwide with disabling consequences. many with a compromised respiratory system cannot support the metabolic energy demands of walking causing them to walk slowly and stop often. those with crd could receive substantial benefit from a powered wearable exoskeleton device that assumes part of the energy of walking. assisting the legs will lower the metabolic energy demands, and therefore the ventilation required for exercise, thereby allowing them to walk faster and further. proposed is a series of single-case experiments comparing walking endurance with and without a powered hip exoskeleton assist. the aim of this study is to determine the efficacy of an exoskeleton on walking endurance in ventilatory limited patients with crd. an exoskeleton could be a novel immediate and long term strategy to augment walking as part of the spectrum of pulmonary rehabilitation and community reintegration.


Eligibility criteria:
inclusion criteria: * stable chronic respiratory disease * modified medical research council dyspnoea score (mmrc) ≥ 2 exclusion criteria: * evidence of cardiac rhythm or circulatory compromise * myocardial infarct within the previous three months * moderate-severe aortic stenosis * uncontrolled hypertension * sustained cardiac arrhythmias * untreated neoplasia * lung surgery within the previous three months * any other predominant co-morbidities or treatments that might influence walk testing * body size outside of exoskeleton fit specifications * skin sores or skin breakdown in the area where the device is worn * a high risk of fracture

Keywords: walking exoskeleton device
macular function during anti-vegf treatment

Conditions: Age Related Macular Degeneration

Summary: the purpose of this study is to determine the changes in macular function during anti-vegf treatment for neovascular age-related macular degeneration.

macular function will be investigated using visual acuity, contrast sensitivity, mferg and microperimetry.

Eligibility criteria:
inclusion criteria: * neovascular amd in first or second eyes * angiographic signs of active subfoveal or juxtafoveal choroidal neovascularization (cnv) * bcva ≥35 etdrs letters exclusion criteria: * spherical equivalent ≥ ± 6 d * previous treatments for cnv in the studied eye
effects of enriched gardens in nursing home residents with dementia

Conditions: Alzheimer Disease

Summary: comparing the effect of the frequentation of an enriched garden vs sensory conventional garden by nursing home residents with alzheimer disease. the effects will be evaluated as regards to cognitive impairment (mmse), autonomy (adl) and prevention of falls (unipodal stance and upandgo test)

the cluster controlled trial is conducted over a six months period after recruitment of residents from 4 different nursing homes in france. the participants are distributed into 3 groups. one group does not receive incentive from carers to visit any garden, the second group receives incentives to visit regularly a conventional sensory garden and the third group receive incentives from carers to visit regularly an enriched garden. the study is conducted over a period of 6 months. all participants are giving consent to the study. they will be evaluated before and after over 4 different tests. mmse (mini mental status examination) for cognitive impairment, adl (activity for day living) for functional autonomy, tug (test up and go) and unipodal stance for prevention of falls.

Eligibility criteria:
inclusion criteria: * give consent * ability walking alone * alzheimer's disease exclusion criteria: * no dementia * severe dementia * severe behavioural disorder * inability to walk alone

Keywords: alzheimer enriched garden enriched environment dementia cognitive impairment functional autonomy
evaluation of electrical nerve stimulation (tens) therapy for pain relief following total knee arthroplasty (tka)

Conditions: Osteoarthritis, Knee; Arthritis; Pain

Summary: evaluation of electrical nerve stimulation (tens) therapy for pain relieft following total knee arrhtoplasty (tka)

a prospective, randomized postmarket trial to assess the efficacy of the select tens™ pain management system, a transcutaneous electrical nerve stimulation (tens) device, for reducing pain and narcotics requirement in patients managed with a total knee arthroplasty (tka). this will be a placebo-controlled study involving 116 patients undergoing primary unilateral tka procedures; 58 patients will be randomly selected to be treated postoperatively with an active tens unit and the other 58 patients will be randomly selected to be treated with the placebo tens unit (control group). patients will be enrolled at two sites within the cleveland clinic health system (main campus and lutheran hospital). both treatment and control groups will receive a femoral nerve catheter, standard during a primary tka. it is hypothesized that tens (in combination with a femoral nerve catheter) can reduce narcotic usage, reduce pain, and allow for a quicker return to function following tka.

Eligibility criteria:
inclusion criteria: * patients undergoing unilateral primary total knee arthroplasty * patients who are between the ages of 18-85 years * patient has signed informed consent exclusion criteria: * patients who live \>100 miles from the cleveland clinic main campus (9500 euclid ave., cleveland, oh 44195) * patients who will not receive a femoral nerve catheter for surgery * patients who are not planned to be discharged directly home following surgery * patients who have used a tens device in the past * preoperative daily use of narcotics (i.e., high tolerance) * already enrolled in another research study, including the present study for contralateral knee * patients with a history of epilepsy * patients with a cardiac pacemaker * patients who are a risk for poor compliance or have a poor understanding of the use of the tens device * condition deemed by physician or medical staff to be non-conducive to patient's ability to complete the study, or a potential risk to the patient's health and well-being.

Keywords: total knee arthroplasty (tka) transcutaneous electrical nerve stimulation (tens) pain function knee osteoarthritis
combined epidural morphine and midazolam on postoperative pain

Conditions: Acute Postoperative Pain

Summary: this study aim to compare the effect of preoperative epidural midazolam, morphine and their combination in postoperative pain relief and total morphine consumption.

major abdominal surgeries with abdominal incisions lead to severe abdominal pain, which if treated inadequately, can cause shallow breathing, atelectasis, retention of secretions and lack of cooperation in physiotherapy. this increases the incidence of post-operative morbidity and leads to delayed recovery.epidural anesthesia is safe and inexpensive technique with the advantage of providing surgical anesthesia and prolonged postoperative pain relief. it also an effective treatment of operative pain blunts autonomic, somatic and endocrine responses. morphine and midazolam can be used as adjuvant to bupivicain to reduced the postoperative pain

Eligibility criteria:
inclusion criteria: * asa i-ii patients scheduled for major abdominal cancer surgeries exclusion criteria: * patients with known allergy to the study drugs, * significant cardiac, respiratory, renal or hepatic disease, * drug or alcohol abuse, * psychiatric illness that would interfere with perception and assessment of pain.

Keywords: epidural, morphine, midazolam, acute postoperative pain
efficacy study of cognitive behavioural treatment with support on communication and information technologies for the management of chronic low back pain

Conditions: Low Back Pain

Summary: the objective of this study is to investigate the short- and long-term efficacy of a cognitive behavioural treatment program for chronic low back pain supported by information and communication technologies

background: psychological treatments have been successful in the treatment of chronic low back pain (clbp). however the effect sizes are still modest and there is room for improvement. a way to progress in this line is enhancing treatment adherence and self-management by means of information and communication technologies (ict). the objective of this study is to investigate the short- and long-term efficacy of a cognitive behavioural treatment (cbt) group program for clbp supported versus non-supported by icts. a secondary objective is to evaluate the influence of relevant variables in treatment response. possible barriers in the implementation of cbt with and without ict will be also investigated. methods: a randomized controlled trail with 180 clbp patients recruited in specialized care will be conducted. participants will be randomly assigned to three conditions: control group (cg), cognitive behavioural program (cbt), and cbt supported by icts (cbt + ict). participants belonging to the three conditions will receive a conventional rehabilitation program (back school). the cbt group program will last six sessions. the cbt + ict will use the internet and sms in order to practice the therapeutic strategies between sessions and in the follow-ups in their homes. primary outcome variables are self-reported disability and pain intensity. assessment will be carried out by blinded assessors in five moments: pre-treatment, post-treatment and 3-, 6-, and 12-month follow-up. the influence of catastrophizing, fear-avoidance beliefs, anxiety and depression in response to treatment in the primary outcomes will be also analysed. discussion this study will show data of the possible benefits of the use of icts in the improvement of cbt for the treatment of clbp

Eligibility criteria:
inclusion criteria: * age between 20 and 65 years * suffering low back pain for at least 6 months * availability of mobile phone in order to get sms * access to computer with internet connection in order to be able to use the cbt program supported by ict exclusion criteria: * mental retardation * not proficient in spanish * neurogenic claudication or neurologic deficit * history of vertebral fracture, previous lumbar surgery * vertebral infection * spinal or nerve tumor * severe mental disorder or substance abuse or dependence.

Keywords: low back pain cognitive behavioural treatment internet disability
the effect of emotional working memory training on reducing depressive symptoms

Conditions: Depressive Symptoms

Summary: the purpose of this study is to test whether emotional working memory training and attention bias modification training are an effective neurobehavioral therapy to improve depressive symptoms.that is whether emotional working memory training is superior to attention bias modification training or not in reducing depressive symptoms over 1 year after training.

attentional bias has been theorized to play a critical role in the onset and maintenance of depression. attentional bias modification training (abmt), an experimental paradigm that uses training to induce adaptive attentional bias, was developed to test the causal model and this has therapeutic implications in depression.to test the effect of abmt on treatment of depressive symptoms, a randomized, double-blind, placebo and blank controlled trial is conducted in college students who are experiencing mild-to-severe symptoms of depression.

Eligibility criteria:
inclusion criteria: meet the major and mild depression disorder's criteria exclusion criteria: bipolar disorder, schizophrenia or organic mental disorder; any concurrent psychotherapy; any concurrent psychotropic medication.

Keywords: depression cognitive control emotion working memory cognitive bias emotional regulation
a real world study on fabulous® thoracic aortic stent system for stanford b aortic dissection

Conditions: Aortic Dissection

Summary: a multicenter, retrospective study to evaluate the real-world efficacy of the fabulous thoracic aortic stent system in the treatment of stanford type b aortic dissection.

fabulous thoracic aortic stent system is specially designed for aortic dissection based on petticoat technique.

Eligibility criteria:
inclusion criteria: * ≥18 years old, regardless of gender; * subject was diagnosed with stanford type b dissection and treated with fabulous thoracic aortic stent system, including either a covered stent system, a bare stent, or both; * with appropriate arterial access and suitable for endovascular aortic repair; * subjects could understand the purpose of the trial, volunteered to participate in the study, signed the informed consent form by themselves or their legal representatives, and were willing to complete the follow-up as required by the protocol. exclusion criteria: * patients have participated in clinical trials of other drugs or medical devices related to target lesion treatment or have participated in clinical trials of other drugs or medical devices and have not reached the primary endpoint; * patients were unable or unwilling to participate in the study; * patients were judged by the investigator to be ineligible for participation in the trial.

Keywords: aortic dissection
locally delivered metformin and aloe vera for treatment of intrabody defects in chronic periodontitis

Conditions: Chronic Periodontitis

Summary: metformin (mf), a biguanide group of anti-diabetic drug has been shown to enhance osteoblasts differentiation and inhibit osteoclast differentiation in vitro, thus may exhibit a favorable effect on alveolar bone. aloevera gel had also been used in dentistry and showed good results.the present study aims to explore the efficacy of 1% mf gel and aloe vera gel as a local drug delivery system in adjunct to scaling and root planing (srp) for the treatment of subjects with chronic periodontitis (cp) with intrabody defects.

aim: to compare the efficacy of locally delivered 1% mf gel and aloe vera gel in treatment of intrabony defects in chronic periodontitis subjects and compare it with placebo gel. methods: ninety subjects were categorized into three treatment groups: placebo, aloevera gel(av) and 1% metformin (mf)after scaling and root planning (srp). clinical parameters were recorded at baseline, 6 and 12 months; they included plaque index (pi), modified sulcus bleeding index (msbi), pocket probing depth (ppd), and clinical attachment level (cal). radiologic assessment of intra-bony defect (ibd) and percentage defect depth reduction (ddr%) was done at baseline, 6 months and 12 months interval using computer-aided software results: mean ppd reduction and mean cal gain was found to greater in mf group than av and placebo group at all visits. the ddr% was greater in mf group as compared to av and placebo group. conclusion: there was a greater decrease in msbi and ppd and more cal gain at the sites treated with av and mf as an adjunct to srp in chronic periodontitis subjects with intrabony defects as compared to placebo. the significant ibd depth reduction effect was seen in case of mfgroup.

Eligibility criteria:
inclusion criteria: systemically healthy patients with sites showing ppd ≥ 5 mm, cal ≥ 4 mm and vertical bone loss ≥ 3 mm on intraoral periapical radiographs, with no history of periodontal therapy in the last 6 months. - exclusion criteria: * subjects allergic to mf or av those on systemic mf or av therapy subjects with aggressive periodontitis immunocompromised subjects use of tobacco in any form, alcoholics lactating, and pregnant females
quality of postoperative analgesia and functional recovery after elective cesarean delivery

Conditions: Obstetric Pain

Summary: based on randomization, patients will receive a mixture for spinal anesthesia and will be followed in the following hours for the various outcomes and for functional recovery

in the study intervention group every patient will receive a spinal anesthesia composed by hyperbaric bupivacaine 12 mg 0,5 %, morphine sulfate 100 mcg and an added randomized dose of 10 or 20 mcg it fentanyl. the spinal anesthetic will be administered with a 27 gauge whitacre needle at the l2-3 or l3-4 intervertebral space with the patient in sitting position. sterile saline will be used to dilute the mixture to a final volume of 3.1 ml. the allocated treatment will be kept a secret from the patient, the anesthesiologist managing the patient, and the entire study team. the fentanyl doses will be prepared by an anesthesiologist who will not be involved in the study or the patient's treatment. for 24 hours following surgery, each patient would receive intravenous patient-controlled morphine analgesia. in the control group every patient will receive a spinal anesthesia composed by hyperbaric bupivacaine 12 mg 0,5 % and morphine sulfate 100 mcg. the spinal anesthetic will be administered with a 27- gauge whitacre needle at the l2-3 or l3-4 intervertebral space with the patient in sitting position. sterile saline will be used to dilute the mixture to a final volume of 3.1 ml. the allocated treatment will be kept a secret from the patient, the anesthesiologist managing the patient, and the entire study team. for 24 hours following surgery, each patient would receive intravenous patient- controlled morphine analgesia.

Eligibility criteria:
inclusion criteria: * patients over 18 year of age * height over 160 cm * american society anesthesiologists physical status i and ii * term singleton parturients * scheduled for elective cesarean delivery during spinal anesthesia at ospedale regionale bellinzona valli exclusion criteria: * patients with inability to consent * patient refusal * contraindication to spinal anesthesia (eg, hemodynamic instability, infection at the surgery site, and neurologic defects such as transverse myelitis) * emergency cesarean delivery * preeclampsia/eclampsia * allergy to drugs used in the protocol

Keywords: cesarean section fentanyl functional recovery
early predictive factors of cardiac and cerebral involvement in tma

Conditions: Thrombotic Microangiopathies; Thrombotic Thrombocytopenic Purpura

Summary: the aim of this study is to determine the frequency of cardiac and cerebral involvements in patients with idiopathic thrombotic microangiopathies on diagnosis. patients will be assessed for cardiac involvement (troponin ic level and cardiac ultrasonography) and cerebral involvement (cerebral mri). the investigators will assess whether serum troponin ic on diagnosis can predict morbidity and mortality of patients with a thrombotic microangiopathy at the acute phase. the primary outcome measurement is the event free survival at day 30, as defined by death, myocardial ischemia, arrhythmia, severe cerebral injury and disease exacerbation. an increase in troponin ic on diagnosis is defined as at least one result above 0.2 ng/ml among the three daily analyses performed after tma diagnosis.

after tma diagnosis, patients will be treated in emergency according to standard national recommendations. patient will be included in the study as soon as the diagnosis of tma is performed. from day 1 to day 3, specific blood tests will be performed (serum troponin ic and brain natriuretic peptide \[bnp\]). a cardiac ultrasonography within the 4 first days and a cerebral mri within the first 7 days after tma diagnosis will be performed. our hypothesis is that an increased serum troponin ic level on diagnosis (\> 0.2 ng/ml) is a predictive feature of cardiac events or worsening at the acute phase. at 6 months, a control cardiac ultrasonography and cerebral mri will be performed in patients with cardiac and/or cerebral involvement on diagnosis. 122 patients are expected to be included among 30 recruiting centres in france. the total duration of inclusions is 2.5 years, and the total duration of the study is of 3 years.

Eligibility criteria:
inclusion criteria: * a diagnosis of thrombotic microangiopathy on the following criteria : * a microangiopathic haemolytic anaemia (hb\< 12 g/dl, with presence of schistocytes on blood smear); * a thrombocytopenia \<150 g/l; * no associated (precipitating) disease (hiv infection, cancer, chemotherapy, transplantation) or pregnancy; * a written consent obtained from the patient, or from a relative for patients unable to provide the informed consent (because of cerebral involvement for example); * affiliation at the social insurance regimen. * major person exclusion criteria: * a tma associated with an associated condition: infection with hiv (hiv) in aids stage, , chemotherapy, malignancy, transplantation, or pregnancy.

Keywords: thrombotic microangiopathy, haemolytic uremic syndrome, thrombotic thrombocytopenic purpura, adamts13, troponin, plasma exchange.
description of changes in nirs as a function of ductus arteriosus status in very premature babies born before 32 wg at the dijon university hospital

Conditions: Extremely Premature Newborn (Born Before 32 Weeks' Gestation)

Summary: monitoring patent ductus arteriosus is currently performed using echocardiography, an operator-dependent examination which requires holding the child on their back and which is potentially time-consuming. this test is usually carried out on days 2, 4 and 7 after birth. nirs (near-infrared spectroscopy) is a non-invasive method of monitoring tissue oxygen saturation using infrared light. the aim of the study was to investigate an association between cerebral and renal nirs data and ductus arteriosus status obtained by echocardiography.


Eligibility criteria:
inclusion criteria: * parent who has agreed to participate in the study * very premature newborn (born before 32 weeks' gestation) * hospitalised in the neonatal intensive care unit at dijon university hospital * before 48 hours of life exclusion criteria: * newborn with congenital heart disease * newborn with a congenital renal anomaly * newborn with polymalformative syndrome * newborn with a skin anomaly * newborn with severe circulatory failure unrelated to the ductus arteriosus
the impact of tamoxifen and aromatase inhibitors on platelet proteins

Conditions: Breast Cancer

Summary: single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.


Eligibility criteria:
inclusion criteria: * women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist exclusion criteria: * use of heparin, warfarin

Keywords: tamoxifen aromatase inhibitors breast cancer platelets